blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3319622

EP3319622 - METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  31.03.2023
Database last updated on 30.03.2026
FormerThe patent has been granted
Status updated on  10.01.2020
FormerGrant of patent is intended
Status updated on  03.09.2019
FormerExamination is in progress
Status updated on  17.07.2019
FormerGrant of patent is intended
Status updated on  03.03.2019
FormerExamination is in progress
Status updated on  13.04.2018
FormerThe international publication has been made
Status updated on  05.07.2017
Formerunknown
Status updated on  25.01.2017
Most recent event   Tooltip31.03.2023Revocation of patentpublished on 03.05.2023  [2023/18]
Applicant(s)For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2021/10]
Former [2018/20]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / ROOS, Tilmann
Kirchentellinsfurter Strasse 16
72127 Kusterdingen / DE
02 / KUNZE, Martin
Gelber Kreidebusen 31
72108 Rottenburg / DE
03 / YAZDAN PANAH, Benyamin
Goethestrasse 11
72076 Tübingen / DE
04 / YILMAZ, Salih
Birkenharder Straße 10
88400 Biberach an der Riß / DE
05 / CONZELMANN, Markus
Steinlachallee 24
72072 Tübingen / DE
 [2020/07]
Former [2018/20]01 / ROOS, Tilmann
Kirchentellinsfurter Strasse 16
72127 Kusterdingen / DE
02 / KUNZE, Martin
Gelber Kreidebusen 31
72108 Rottenburg / DE
03 / YAZDAN PANAH, Benyamin
Goethestrasse 11
72076 Tübingen / DE
04 / YILMAZ, Salih
Untere Höhbergstr. 18
72074 Tübingen / DE
05 / CONZELMANN, Markus
Steinlachallee 24
72072 Tübingen / DE
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2020/07]Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2018/20]Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date16826337.422.12.2016
[2018/20]
WO2016EP82487
Priority number, dateWO2015EP8100022.12.2015         Original published format: PCT/EP2015/081000
[2018/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017109134
Date:29.06.2017
Language:EN
[2017/26]
Type: A1 Application with search report 
No.:EP3319622
Date:16.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 29.06.2017 takes the place of the publication of the European patent application.
[2018/20]
Type: B1 Patent specification 
No.:EP3319622
Date:12.02.2020
Language:EN
[2020/07]
Search report(s)International search report - published on:EP29.06.2017
ClassificationIPC:A61K38/00, A61K39/00, A61K48/00
[2018/20]
CPC:
A61K39/12 (EP,KR,US); C07K14/005 (EP,KR,US); A61P21/00 (EP,US);
A61P31/00 (EP,US); A61P39/00 (EP,US); C12N15/1024 (US);
C12Q1/6844 (EP,KR,US); C40B40/02 (US); C40B40/08 (US);
A61K2039/53 (EP,KR,US); A61K2039/70 (EP,KR,US); A61K38/00 (EP,US);
C12N2760/16111 (EP,KR,US); C12N2760/16122 (EP,KR,US); C12N2760/16134 (EP,KR,US);
C12N2760/16222 (EP,KR,US); C12N2760/16234 (EP,KR,US); C12Q2521/119 (KR);
C40B10/00 (US); Y02A50/30 (EP,US) (-)
C-Set:
C12Q1/6844, C12Q2521/119 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG VON RNA-MOLEKÜL-ZUSAMMENSETZUNGEN[2018/20]
English:METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS[2018/20]
French:PROCÉDÉ DE PRODUCTION DE COMPOSITIONS DE MOLÉCULES D'ARN[2018/20]
Entry into regional phase06.02.2018National basic fee paid 
06.02.2018Designation fee(s) paid 
06.02.2018Examination fee paid 
Examination procedure16.08.2017Request for preliminary examination filed
International Preliminary Examining Authority: EP
06.02.2018Amendment by applicant (claims and/or description)
06.02.2018Examination requested  [2018/20]
06.02.2018Date on which the examining division has become responsible
17.04.2018Despatch of a communication from the examining division (Time limit: M04)
23.08.2018Reply to a communication from the examining division
28.09.2018Despatch of a communication from the examining division (Time limit: M04)
01.02.2019Reply to a communication from the examining division
04.03.2019Communication of intention to grant the patent
12.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.09.2019Communication of intention to grant the patent
30.12.2019Fee for grant paid
30.12.2019Fee for publishing/printing paid
30.12.2019Receipt of the translation of the claim(s)
Divisional application(s)EP20156569.4  / EP3701963
Opposition(s)Opponent(s)01  12.11.2020   
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Opponent's representative
Thomann, William John
ZSP
Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 [2020/51]
25.11.2020Invitation to proprietor to file observations on the notice of opposition
01.04.2021Reply of patent proprietor to notice(s) of opposition
05.10.2022Date of oral proceedings
05.10.2022Legal effect of revocation of patent [2023/18]
15.12.2022Despatch of minutes of oral proceedings
15.12.2022Despatch of communication that the patent will be revoked
Fees paidRenewal fee
19.12.2018Renewal fee patent year 03
23.12.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.12.2016
AL12.02.2020
AT12.02.2020
CY12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MK12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE22.12.2020
LU22.12.2020
[2022/31]
Former [2022/30]HU22.12.2016
AL12.02.2020
AT12.02.2020
CY12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE22.12.2020
LU22.12.2020
Former [2022/27]HU22.12.2016
AT12.02.2020
CY12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE22.12.2020
LU22.12.2020
Former [2021/47]AT12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE22.12.2020
LU22.12.2020
Former [2021/46]AT12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE22.12.2020
Former [2021/40]AT12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2021/10]AT12.02.2020
CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/50]CZ12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/49]CZ12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/48]ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/47]ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/45]FI12.02.2020
HR12.02.2020
LV12.02.2020
NL12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/40]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/39]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
Former [2020/38]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
NO12.05.2020
GR13.05.2020
Former [2020/37]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
NO12.05.2020
Former [2020/35]FI12.02.2020
NO12.05.2020
Cited inInternational search[XDY] WO2015024669  (CUREVAC GMBH et al.) [XD] 30-39 * examples 1-5; claims 1-35 *[Y] 3-15,17,18,20-22,27-29
 [XY]   SUSAN BENNETT ET AL: "Rapid Simultaneous Detection of Enterovirus and Parechovirus RNAs in Clinical Samples by One-Step Real-Time Reverse Transcription-PCR Assay", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 49, no. 7, 1 July 2011 (2011-07-01), US, pages 2620 - 2624, XP055235243, ISSN: 0095-1137, DOI: 10.1128/JCM.02445-10 [X] 1,2,16,19,23-26 * page 2621, column 1, paragraph 2 - page 2621, column 2, paragraph 1 * * page 2623, column 1, paragraph 2 *[Y] 3-15,17,18,20-22,27-29

DOI:   http://dx.doi.org/10.1128/JCM.02445-10
 [XY]   JIN LI ET AL: "The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes", BMC INFECTIOUS DISEASES, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 14 August 2012 (2012-08-14), pages 1 - 8, XP021106921, ISSN: 1471-2334, DOI: 10.1186/1471-2334-12-189 [X] 1,2,16,19,23-26 * page 2, column 1, paragraph l - page 5, column 1, paragraph 3; table 2 * * page 7, column 2, paragraph 1 * [Y] 3-15,17,18,20-22,27-29

DOI:   http://dx.doi.org/10.1186/1471-2334-12-189
 [A]   HU X ET AL: "Simultaneously typing nine serotypes of enteroviruses associated with hand, foot, and mouth disease by a GeXP analyzer-based multiplex reverse transcription-PCR assay", February 2012, JOURNAL OF CLINICAL MICROBIOLOGY 2012 AMERICAN SOCIETY FOR MICROBIOLOGY USA, VOL. 50, NR. 2, PAGE(S) 288 - 293, ISSN: 0095-1137, XP002755277 [A] 1-39 * page 290, column 1, paragraph l - page 290, column 2, paragraph 1; figure 3 *

DOI:   http://dx.doi.org/10.1128/JCM.05828-11
 [A]   GEERTRUI TAVERNIER ET AL: "mRNA as gene therapeutic: How to control protein expression", JOURNAL OF CONTROLLED RELEASE, vol. 150, no. 3, 1 March 2011 (2011-03-01), pages 238 - 247, XP055068617, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2010.10.020 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2010.10.020
 [A]   THOMAS KRAMPS ET AL: "Messenger RNA-based vaccines: progress, challenges, applications", WILEY INTERDISCIPLINARY REVIEWS: RNA, vol. 4, 1 July 2013 (2013-07-01), pages 737 - 749, XP055180522, ISSN: 1757-7004, DOI: 10.1002/wrna.1189 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1002/wrna.1189
 [A]   BENJAMIN PETSCH ET AL: "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", NATURE BIOTECHNOLOGY, vol. 30, no. 12, 1 January 2012 (2012-01-01), pages 1210 - 1216, XP055051005, ISSN: 1087-0156, DOI: 10.1038/nbt.2436 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt.2436
 [A]   PASCOLO S: "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, HUMANA PRESS, TOTOWA, NJ, US, 1 January 2006 (2006-01-01), pages 23 - 40, XP009117840, ISSN: 1543-1894 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1385/1-59745-168-1:23
 [A]   ULMER J B ET AL: "Vaccines 'on demand': Science fiction or a future reality", EXPERT OPINION ON DRUG DISCOVERY, INFORMA HEALTHCARE, LONDON, GB, vol. 10, no. 2, 1 February 2015 (2015-02-01), pages 101 - 106, XP008175781, ISSN: 1746-0441, DOI: 10.1517/17460441.2015.996128 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1517/17460441.2015.996128
ExaminationEP1083232
OppositionWO2015135558
   PETSCH ET AL.: "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 1210 - 1216, 1-2, XP055051005

DOI:   http://dx.doi.org/10.1038/nbt.2436
   WILSON ET AL.: "A Template-Selective Inhibitor of In Vitro Transcription", PROC. NAT. ACAD. SCI., vol. 62, 1969, pages 514 - 520, XP055755644
   KAJITANI ET AL.: "Determination of the promoter strength in the mixed transcription system: promoters of lactose, tryptophan and ribosomal protein L10 operons from Escherichia coli", NUCLEIC ACIDS RESEARCH, vol. 11, 1983, pages 671 - 686
   KAJITANI ET AL.: "Promoter Selectivity of Escherichia coli RNA Polymerase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 259, 1984, pages 1951 - 1957
   NOMURA ET AL.: "Promoter selectivity of Escherichia coli RNA polymerase: alteration by fMet-tRNAfMet", NUCLEIC ACIDS RESEARCH, vol. 14, 1986, pages 6857 - 6870, XP055755650
   LANGERT ET AL.: "Functional Characteristics of the rrnD Promoters of Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, 1991, pages 21608 - 21615, XP055755655
   SHIMADA ET AL.: "The Whole Set of Constitutive Promoters Recognized by RNA Polymerase RpoD Holoenzyme of Escherichia coli", PLOS ONE, vol. 9, 2014, pages e90447, 1 - 22, XP055755657
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.